Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Canaccord Genuity reduced its price target on Aspen Aerogels (NYSE:ASPN) to $10.00 from $11.00 on Thursday, while maintaining a Buy rating on the stock. The company, currently trading at $7.57 with a market cap of $618 million, is considered undervalued according to InvestingPro analysis.
The firm cited "continued uncertainty" as the reason for adjusting its estimates, which led to the price target reduction.
Canaccord’s new target is based on approximately 11 times its 2028 estimated earnings per share, shifting from previous calculations that used 2027 estimates to better reflect the company’s scaled earnings potential.
The research firm noted that the median of Aspen Aerogels’ comparable companies trades at approximately 11 times earnings, a multiple it considers "justified, if not conservative" for ASPN.
Canaccord’s positive long-term outlook for the company stems from Aspen’s "numerous OEM relationships, competitive moat, strong balance sheet, and potential for healthy FCF generation," which support strong growth potential beyond 2027.
In other recent news, Aspen Aerogels Inc . reported its Q2 2025 earnings, delivering a notable performance that exceeded revenue forecasts. The company achieved earnings per share of $0.04, significantly surpassing the anticipated -$0.09, representing a remarkable surprise of 144.44%. Aspen Aerogels reported revenue of $78 million, which also exceeded the projected $72.53 million. These results highlight the company’s ability to outperform financial expectations. This recent development reflects positively on the company’s financial health and operational efficiency. Investors might find these results encouraging as they indicate strong performance in the latest quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.